Breast Cancer
Conditions
Keywords
CR011-vcMMAE, locally advanced breast cancer, metastatic breast cancer, breast cancer, CDX-011, GPNMB, Targeted treatment for breast cancer, Locally advanced or metastatic breast cancer
Brief summary
The main purpose of this study is to see whether CDX-011 is effective in treating patients who have advanced breast cancer that makes a protein called glycoprotein NMB (GPNMB), and who have already received (or were not candidates for) all available approved therapies for their breast cancer. This study will also further characterize the safety of CDX-011 treatment in this patient population.
Detailed description
CDX-011 consists of an antibody attached to a drug, monomethyl auristatin E (MMAE), that can kill cancer cells. The antibody delivers the drug to cancer cells by attaching to a protein called glycoprotein NMB (GPNMB) that is expressed on the cancer cell. The MMAE is then released inside of the cell, where it interferes with cell growth and may lead to cell death. This study will examine the effectiveness and safety of CDX-011 in patients with advanced breast cancer that makes the GPNMB protein. To better assess this, the effect of CDX-011 will be compared to treatment with currently available cancer chemotherapy. Eligible patients who enroll in the study will be randomly assigned by chance to receive treatment with CDX-011 or with a chemotherapy chosen by their study doctor from a list of currently available drugs (Investigator's Choice chemotherapy). For each three patients enrolled, two will receive CDX-011 and one will receive treatment with Investigator's Choice. Patients initially assigned to Investigator's Choice chemotherapy may be offered treatment with CDX-011 if their cancer worsens during this initial treatment. All patients enrolled in the study will be closely monitored to determine if their cancer is responding to treatment, and for any side effects that may occur.
Interventions
DRUGCDX-011
CDX-011 (1.88 mg/kg) administered as an intravenous infusion on Day 1 of each 21 day cycle.
Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
Sponsors
Celldex Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Among other criteria, patients must meet all of the following conditions to be eligible for the study: 1. 18 years of age or older. 2. Locally advanced or metastatic breast cancer. 3. Previous treatment with at least two but no more than seven prior chemotherapy treatments for progressive, recurrent or metastatic breast cancer. 4. Unless not a candidate for these agents, prior therapies must have included a taxane, an anthracycline, and capecitabine, as well as trastuzumab and lapatinib for patients whose tumors are positive for the human epidermal growth factor receptor 2 (HER2). (Patients who received incomplete courses of therapy with these agents due to intolerance will be eligible.) 5. Breast cancer tumor confirmed to express GPNMB. This will be determined by submitting a tissue sample (obtained during a diagnostic biopsy or surgery) to a central laboratory for analysis.
Exclusion criteria
Among other criteria, patients who meet any of the following conditions are NOT eligible for the study: 1. Ongoing neuropathy or other chemotherapy or radiation-related toxicities that are moderate (Grade 2) or worse in severity. 2. Known brain metastases, unless previously treated and asymptomatic for 2 months and not progressive in size or number for 2 months. 3. Significant cardiovascular disease or any other underlying medical condition that, in the Investigator's opinion, will make the administration of study treatment (CDX-011 or chemotherapy) hazardous or would obscure the interpretation of side effects.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate | 6 or more weeks following treatment initiation | The objective response rate (ORR) is defined as the proportion of patients who achieve radiographic partial or complete response (PR or CR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guideline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | At least 18 months following treatment initiation | Progression-free survival is defined as the time from randomization to the earlier of disease progression or death due to any cause. |
| Adverse Events | Usually following at least 1 cycle of study treatment (1 dose of CDX-011 or Investigator's Choice chemotherapy and 3 to 4 weeks of follow-up) | The number and percentage of patients experiencing one or more adverse events will be summarized by treatment arm, relationship to study drug, and severity. |
Countries
United States
Outcome results
None listed